Mechanistic Study of Schisandra chinensis Fruit Mixture Based on Network Pharmacology, Molecular Docking and Experimental Validation to Improve the Inflammatory Response of DKD Through AGEs/RAGE Signaling Pathway
Hongdian Li,Ao Dong,Na Li,Yu Ma,Sai Zhang,Yuanyuan Deng,Shu Chen,Mianzhi Zhang
DOI: https://doi.org/10.2147/DDDT.S395512
2023-02-28
Abstract:Hongdian Li, 1, &ast Ao Dong, 1, &ast Na Li, 1 Yu Ma, 1 Sai Zhang, 1 Yuanyuan Deng, 1 Shu Chen, 1 Mianzhi Zhang 1, 2 1 Department of Nephrology, Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, People's Republic of China; 2 Department of Nephrology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Mianzhi Zhang, Email Background: Diabetic kidney disease (DKD) is a major cause of end-stage renal disease (ESRD), and inflammation is the main causative mechanism. Schisandra chinensis fruit Mixture (SM) is an herbal formulation that has been used for a long time to treat DKD. However, its pharmacological and molecular mechanisms have not been clearly elucidated. The aim of this study was to investigate the potential mechanisms of SM for the treatment of DKD through network pharmacology, molecular docking and experimental validation. Methods: The chemical components in SM were comprehensively identified and collected using liquid chromatography-tandem mass spectrometry (LC-MS) and database mining. The mechanisms were investigated using a network pharmacology, including obtaining SM-DKD intersection targets, completing protein–protein interactions (PPI) by Cytoscape to obtain key potential targets, and then revealing potential mechanisms of SM for DKD by GO and KEGG pathway enrichment analysis. The important pathways and phenotypes screened by the network analysis were validated experimentally in vivo. Finally, the core active ingredients were screened by molecular docking. Results: A total of 53 active ingredients of SM were retrieved by database and LC-MS, and 143 common targets of DKD and SM were identified; KEGG and PPI showed that SM most likely exerted anti-DKD effects by regulating the expression of AGEs/RAGE signaling pathway-related inflammatory factors. In addition, our experimental validation results showed that SM improved renal function and pathological changes in DKD rats, down-regulated AGEs/RAGE signaling pathway, and further down-regulated the expression of TNF-α, IL-1β, IL-6, and up-regulated IL-10. Molecular docking confirmed the tight binding properties between (+)-aristolone, a core component of SM, and key targets. Conclusion: This study reveals that SM improves the inflammatory response of DKD through AGEs/RAGE signaling pathway, thus providing a novel idea for the clinical treatment of DKD. Keywords: Schisandra chinensis fruit mixture, diabetic kidney disease, traditional Chinese medicine, network pharmacology, molecular docking Diabetic kidney disease (DKD) is one of the most serious and common microvascular complications of diabetes and is currently the leading cause of end-stage renal disease (ESRD). According to a comprehensive summary of epidemiological data, diabetes, hypertension or the cumulative effect of both are responsible for 80% of ESRD formation and diabetic patients are 10 times more likely to develop ESRD than non-diabetic population. 1 The prevalence of DKD is increasing in a violent trend with the expansion of the diabetes population. There are currently about 537 million people with diabetes worldwide, and it is expected to increase to 783 million by 2045, of which 30–40% will develop DKD. 2 Patients with ESRD require long-term dialysis or kidney transplantation, which seriously affects their quality of life and survival time, while greatly increasing the socioeconomic burden. 3 The current treatment strategy for DKD is based on symptomatic supportive therapy with strict control of blood glucose and blood pressure levels; however, there are bottlenecks in efficacy. For example, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonist drugs are effective in reducing proteinuria, but hardly prevent the development of renal fibrosis. 4–7 Sodium-glucose-linked transporter-2 inhibitors have been considered in recent years as the most promising new drugs for the treatment of DKD, 8 which control glycemia and diabetes-related complications by inhibiting renal reabsorption of glucose, lowering the renal tissue glucose threshold, and promoting urinary glucose excretion. However, the current evidence from clinical studies is not sufficient. In addition, a recent study has shown that dapagliflozin increases the economic burden of kidney disease treatment in the United States. 9 For these reasons, there is an urgent need to find cost-effective ways to delay the progression of DKD. 10,11 Traditional Ch -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal